AbbVie Inc.
AbbVie Inc. Discloses Third-Quarter Earnings Impact
Summary
AbbVie Inc. announced on October 3, 2024, that its reported GAAP and adjusted non-GAAP earnings for Q3 2024 will include an unfavorable impact of $0.04 per share due to $82 million in acquired IPR&D and milestones expense. This expense is expected to affect both GAAP and adjusted non-GAAP diluted earnings per share. The company's full-year 2024 adjusted diluted earnings per share guidance range is now $10.67 - $10.87, and the Q3 2024 guidance range is $2.88 - $2.92, including this expense. These results are preliminary and subject to change.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement